ReNu™ Marrow Stimulation Augmentation

Evaluation of the ReNu™ Amniotic Suspension Allograft After Marrow Stimulation in the Treatment of Osteochondral Defects

To evaluate the use of ReNu™ allograft for the augmentation of marrow stimulation for osteochondral lesions

Study Overview

• Status: Terminated
• Conditions: Osteochondral Defect
• Intervention / Treatment: Other: ReNu

Detailed Description

This is a prospective, non-randomized, longitudinal study of up to 8 evaluable participants recruited from two separate practices. Male and non-pregnant female patients between the ages of 18 and 55 years of age will be screened for study recruitment. Female patients must be actively practicing a contraception method, abstinence, be surgically sterilized, or be postmenopausal. Participants will receive ReNu™ as an adjunct to their standard of care marrow stimulation for the treatment of osteochondral defects.

At each follow-up visit, concomitant medications and adverse events shall be collected from each subject, and each subject shall complete the following questionnaires:

IKDC Health Assessment (Includes Short Form-36) Tegner KOOS Knee Survey VAS Pain Scale SANE score

The subjects will be assessed at Baseline using these scales an again at all subsequent study follow-up visits.

• Study Type: Interventional
• Enrollment (Actual): 1
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Indiana
    • Indianapolis, Indiana, United States, 46143
      • OrthoIndy
  • New York
    • New York, New York, United States, 10021
      • Hospital for Special Surgery

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Voluntary signature of the IRB approved Informed Consent
2. Male or female participants between the ages of 18-55

3. If female:

   1. Actively practicing a contraception method, or
   2. Practicing abstinence, or
   3. Surgically sterilized, or
   4. Postmenopausal
4. Pretreatment arthroscopic confirmation indicating one or two contained lesion(s) and equal to an ICRS Grade 3a, 3b, 3c, 3d of the femoral condyle, patella, or trochlear groove and OCD lesions (Grade 4a) with healed bone base, which is non-sclerotic and no loss of bone greater then 6mm measured from the surrounding subchondral plate. Original pretreatment arthroscopic confirmation indicates that one or two lesion(s) are equal to an ICRS Grade 3a, 3b, 3c, 3d contained lesion(s) that is equivalent to an Outerbridge Grade III or IV (greater than 50% loss of articular cartilage). OF NOTE: Patients with need for concomitant procedures such as Anteromedialization of Tibial Tubercle (AMZ) and lateral lengthening are allowable
5. Has peripheral cartilage debridement to healthy cartilage that results in a lesion (s) with an area of > or = 1cm ^2 and < or = 4 cm^2.
6. PCL, LCL and MCL in the affected knee are stable and the ACL is stable or can be stabilized as a concomitant procedure.
7. Ipsilateral knee compartment has intact menisci (or requires partial meniscectomy resulting in stable menisci). Minimum remnant width of 5mm.
8. The contralateral knee is asymptomatic, stable, and fully functional.
9. Must be physically and mentally willing and able to comply with post-operative rehabilitation and routinely scheduled clinical and radiographic visits through 24 months.
10. Alignment: Mechanical axis must be no more than 5 degrees from neutral.
11. Must be 3 months post previous surgery.

Exclusion Criteria:

1. Clinical and/or radiographic disease diagnosis of the indexed affected joint that Includes:

   1. Osteoarthritis or avascular necrosis,
   2. Rheumatoid arthritis, or history of septic or reactive arthritis,
   3. Gout or history of gout or pseudogout in the affected knee,
   4. Osteochondritis dissecans of the knee with significant bone loss (greater than 6mm deep from the subchondral plate)
   5. Associated damage to the underlying subchondral bone requiring a bone graft
2. History of secondary arthropathies (i.e. sickle cell disease, hemochromatosis, or autoimmune disease).
3. Uncontrolled diabetes.
4. Displays a high surgical risk due to unstable cardiac and/or pulmonary disease.
5. Has HIV or other immunodeficient state including subjects on immunosuppressant therapies, or has significant illness (metastasis of any type) that decreases the probability of survival to the 2 year endpoint.
6. Is at substantial risk for the need of organ transplantation, such as renal insufficiency.
7. Is pregnant or breast-feeding.
8. Body mass index > 35.
9. Has bipolar articular cartilage involvement or kissing lesions of the ipsilateral compartment, described as tibial or patellar lesions in the same compartment with greater than ICRS Grade 2 chondrosis.
10. Is participating concurrently in another clinical trial, or has participated in a clinical trial within 30 days of surgery.
11. Is receiving prescription pain medication other than NSAIDs or acetaminophen for conditions unrelated to the index knee condition, chronic use of anticoagulants, or taking corticosteroids.
12. Has a neuromuscular, neurosensory, or musculoskeletal deficiency that limits the ability to perform objective functional assessment of either knee.
13. Active joint infection.
14. Prior total meniscectomy of either knee.
15. Radiographically has >5 degrees of malalignment as measured from the hip, knee and ankle mechanical axis.
16. Has subchondral bone loss of greater than 6mm
17. Has received within the past three months intra-articular platelet rich plasma, hyaluronic acid therapy, steroid, amniotic-derived or stem cell injections in the index knee.
18. Prior realignment surgery in the affected knee within the past 6 months.
19. Failed microfracture/marrow stimulation treatment performed less than 12-months before baseline.
20. Is receiving workman's compensation or currently involved in litigation relating to the index knee.
21. Has history of alcoholism, medication, or intravenous drug abuse, psychosis, is a prisoner, has a personality disorder (s), poor motivation, emotional or intellectual issues that would likely make the subject unreliable for the study, or any combination of variables in the investigator's judgment that should exclude a potential subject.
22. Any conditions or implants that might affect having MRIs: had or have an aneurysm clip implanted, intraocular foreign bodies (commonly seen in welders), subcutaneous metal shards (found in sheet metal workers), or some shrapnel; additionally, no cardiac pacemaker, defibrillator, implanted neurostimulater (TENS implants) some prosthetic heart valve (especially mitral valve), cochlear implant or other hearing aide. Subjects should be excluded if they have a tendency of claustrophobia or have tattoos that may contain iron-based dyes.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ReNu Injection; Injection of ReNu allograft into the joint capsule.	Other: ReNu; ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change in KOOS score from baseline	1 Year
Change in Tegner score from baseline	1 Year

Secondary Outcome Measures

Outcome Measure	Time Frame
Change in VAS score from baseline	6, 12 & 24 months
Change in Tegner score from baseline	6 & 24 months
Change in SANE score from baseline	6, 12 & 24 months
Change in KOOS score from baseline	6 & 24 months

Collaborators and Investigators

• Sponsor: NuTech Medical, Inc
• Collaborators: Organogenesis

Study record dates

Study Major Dates

• Study Start (Actual): February 7, 2017
• Primary Completion (Actual): December 6, 2019
• Study Completion (Actual): December 6, 2019

Study Registration Dates

• First Submitted: January 27, 2017
• First Submitted That Met QC Criteria: January 27, 2017
• First Posted (Estimate): January 30, 2017

Study Record Updates

• Last Update Posted (Actual): January 18, 2020
• Last Update Submitted That Met QC Criteria: January 13, 2020
• Last Verified: January 1, 2020

More Information

Terms related to this study

• Keywords: Osteochondral; ReNu; Marrow Stimulation
• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Bone Diseases; Osteochondrosis
• Other Study ID Numbers: RD-2016-04-02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No